Trial Profile
A retrospective, cohort study of ranibizumab and aflibercept in patients with central retinal vein occlusion
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Central retinal vein occlusion
- Focus Therapeutic Use
- 10 Nov 2016 New trial record
- 02 Nov 2016 Results of preliminary analysis presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.